Linked Life Data

16430192

Source:http://linkedlifedata.com/resource/pubmed/id/16430192

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2006-1-24
pubmed:abstractText
The emerging epidemic of H5N1 avian influenza virus with spillover into the human population in Asia has provoked intense concern globally about the potential of these particularly pathogenic viruses to evolve with the capacity for human-to-human transmission with a consequent pandemic. The availability of antiviral drugs with activity against influenza A viruses and the recognition of drug-resistant variants to these drugs prompted the following report by a select group of the global experts--members of the Neuraminidase Inhibitor Susceptibility Network--on the best use of the available drugs, both for prophylaxis and treatment. The editors of Antiviral Therapy are pleased to be able to provide this document in an expeditious manner.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1359-6535
pubmed:author
pubmed:issnType
Print
pubmed:volume
10
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
873-7
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses.
pubmed:affiliation
Division of Infectious Disease and International Health, Department of Internal Medicine, University of Virginia School of Medicine, Charlottesville, VA, USA. FGH@Virginia.edu
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't